Transplantation of Hematopoietic Progenitors From Haploidentical Donor With Selective in Vitro Depletion Allo-reactive Lymphocytes in Patient With High Risk Hematological Malignancies

Transplantation of Hematopoietic Progenitors From Haploidentical Donor With Selective in Vitro Depletion Allo-reactive Lymphocytes in Patient With High Risk Hematological Malignancies.

Therapeutic exploratory study to evaluate safety, open, nonrandomized, multicentre, prospective, of cohort of patients who will receive different doses of allo-depleted lymphocytes .

This project joins in this pioneering worldwide initiative with its own technology based on the use of proteasome inhibitors in vitro, which advantages are, over other methods described, the continuing viability of regulatory T cells and the use of a product to generate allo-depletion that, contrary to those reported by other research groups, it does not pose problems from the point of view of its use or toxicity as we employ a drug widely used clinically by intravenous administration.

Study Overview

• Status: Withdrawn
• Conditions: Transplant-Related Hematologic Malignancy
• Intervention / Treatment: Other: Haploidentical transplantation of hematopoietic progenitors; Other: Allo-depleted lymphocyte infusion

Detailed Description

The main objective of the study is to determine the safety of transplantation of hematopoietic progenitors from haploidentical donor with in vitro allo-depleted lymphocyte infusion.

Secondary objectives:

• To assess the immune reconstitution pre and post-infusion of allo-depleted lymphocytes.
• To analyze the incidence of infections (CMV and aspergillus) post-transplant.
• To analyze the impact of acute and chronic graft-versus-host disease (GVHD).
• To optimize the dose of allo-depleted lymphocytes to reconstitute an immune response against pathogens without causing GVHD.
• To assess the rate of graft and myeloid and platelet engraftment time.
• To assess the rate of relapses, event-free survival and overall survival. It is hoped to recruit 20 clinically evaluable patients for safety purpose.

The inclusion period is not more than 2 ½ years. Study duration shall not exceed three years from the inclusion of the first patient. The minimum follow-up of patients is 6 months after transplantation.

The first 5 patients (group 0) will receive haploidentical transplantation of hematopoietic progenitors without subsequent infusion of allo-depleted lymphocytes and then in cohorts of 3 patients, infuse +4 post-transplant day at doses of: 1x105 cluster of differentiation 3 (CD3)/kg(group 1), 3x105 CD3/kg (group 2), 5x105 CD3 / kg (group 3), 1x106 CD3/kg (group 4) and 3x106 CD3/kg (group 5).

Donor: it is performed one leukapheresis at least 30 days (4 weeks) prior to the scheduled progenitors infusion (day 0), in order to obtain effector T cells.

• Study Type: Interventional
• Phase: Phase 1

Contacts and Locations

Study Locations

• Spain
  • Cordoba, Spain, 14004
    • University Hospital Reina Sofía
  • Malaga, Spain, 29010
    • University Hospital Carlos Haya
  • Salamanca, Spain, 37007
    • University Hospital de Salamanca
  • Sevilla, Spain, 41013
    • University Hospital Virgen del Rocio

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 16 years to 50 years (Child, Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Adult patients aged between 16 and 50 years.
• Diagnosed as Hematological malignancy candidates to allogeneic transplant lacking of related or unrelated suitable donor (is more than one Human leukocyte antigen (HLA) mismatched over 8 antigens) and who don't have a cord with an adequate cellularity. The minimum period of search to be able to include the patient in the trial, currently considering the medium to find a suitable donor to be 2 months, it is set to 10 weeks, although in specific situations in which the responsible physician considers that the patient has a high risk of relapse, it may be proceed with inclusion before that period. These cases will be assessed individually with the trial coordinator.

Exclusion Criteria:

• General condition> Eastern Cooperative Oncology Group (ECOG) scale 2.
• Left Ventricular ejection fraction (LVEF) <39%.
• Diffusion capacity of lung for carbon monoxide (DLCO) and forced vital capacity (FVC) <39% of the theoretical values.
• Impaired liver function (total bilirubin higher than 2 mg / dL and / or transaminases higher than 3 times the normal maximum.
• Creatinine clearance <50 mL / minute.
• Presence of symptomatic heart, liver cirrhosis or chronic active hepatitis.
• Active tuberculosis.
• Serious diseases which prevent chemotherapy treatments.
• Associated neoplasias (active neoplasias which, according to the opinion of the investigator and the sponsor, could jeopardize patient safety).
• Presence of associated psychiatric pathology.
• HIV infection.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

6

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Placebo Comparator: Group 0; Haploidentical transplantation of hematopoietic progenitors	Other: Haploidentical transplantation of hematopoietic progenitors; Haploidentical transplantation of hematopoietic progenitors without subsequent infusion of allo-depleted lymphocytes.
Experimental: Group 1; Allo-depleted lymphocyte infusion dose: 1x105 CD3/Kg	Other: Allo-depleted lymphocyte infusion; Doses: 1x105 CD3/Kg; 3x105 CD3/Kg; 5x105 CD3/Kg; 1x106 CD3/Kg;31x106 CD3/Kg;
Experimental: Group 2; Allo-depleted lymphocyte infusion dose: 3x105 CD3/Kg	Other: Allo-depleted lymphocyte infusion; Doses: 1x105 CD3/Kg; 3x105 CD3/Kg; 5x105 CD3/Kg; 1x106 CD3/Kg;31x106 CD3/Kg;
Experimental: Group 3; Allo-depleted lymphocyte infusion dose: 5x105 CD3/Kg	Other: Allo-depleted lymphocyte infusion; Doses: 1x105 CD3/Kg; 3x105 CD3/Kg; 5x105 CD3/Kg; 1x106 CD3/Kg;31x106 CD3/Kg;
Experimental: Group 4; Allo-depleted lymphocyte infusion dose: 1x106 CD3/Kg	Other: Allo-depleted lymphocyte infusion; Doses: 1x105 CD3/Kg; 3x105 CD3/Kg; 5x105 CD3/Kg; 1x106 CD3/Kg;31x106 CD3/Kg;
Experimental: Group 5; Allo-depleted lymphocyte infusion dose: 3x106 CD3/Kg	Other: Allo-depleted lymphocyte infusion; Doses: 1x105 CD3/Kg; 3x105 CD3/Kg; 5x105 CD3/Kg; 1x106 CD3/Kg;31x106 CD3/Kg;

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Number of adverse events and serious adverse events after allo-depleted lymphocyte infusion in vitro.	6 months

Secondary Outcome Measures

Outcome Measure	Time Frame
Incidence of acute and chronic GVHD	6 months

Collaborators and Investigators

• Sponsor: Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud
• Collaborators: Iniciativa Andaluza en Terapias Avanzadas
• Investigators: Principal Investigator: Jose-Antonio Perez-Simón, MD, PhD, University Hospital Virgen del Rocio; Principal Investigator: Antonio Torres, MD, PhD, University Hospital Reina Sofía; Principal Investigator: Lucía Lopez-Corral, MD, PhD, University Hospital de Salamanca; Principal Investigator: Mª Ángeles Cuesta, MD, PhD, University Hospital Carlos Haya

Publications and helpful links

Helpful Links

• Andalusian Molecular Biology and Regenerative Medicine Centre
• Andalusian Initiative for Advanced Therapies

Study record dates

Study Major Dates

• Study Start: January 1, 2013
• Primary Completion (Anticipated): December 1, 2018
• Study Completion (Anticipated): December 1, 2018

Study Registration Dates

• First Submitted: December 13, 2012
• First Submitted That Met QC Criteria: December 13, 2012
• First Posted (Estimate): December 17, 2012

Study Record Updates

• Last Update Posted (Actual): July 6, 2018
• Last Update Submitted That Met QC Criteria: July 4, 2018
• Last Verified: September 1, 2017

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Neoplasms by Site; Hematologic Diseases; Neoplasms; Hematologic Neoplasms
• Other Study ID Numbers: ALODEPLETE